In the wake of mass restructuring efforts across the Department of Health and Human Services, the FDA has missed yet another ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic ...

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

Dr Vinay Prasad, an oncologist and outspoken critic of the FDA leadership and COVID-19 mandates has been named as the new ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.

The Food and Drug Administration (FDA) has named Indian American hematologist-oncologist Dr. Vinay Prasad, an outspoken ...

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.

The FDA has appointed hematologist-oncologist Vinay Prasad, MD, to lead the agency’s Center for Biologics Evaluation and Research, according to a May 6 NBC News report.  As the head of CBER, Dr.